| scholarly article | Q13442814 |
| P2093 | author name string | Annemieke Aartsma-Rus | |
| Roula Tsonaka | |||
| Alexandre Seyer | |||
| Pietro Spitali | |||
| Kristina Hettne | |||
| Mirko Signorelli | |||
| Ekrem Sabir | |||
| P2860 | cites work | Cytoscape: a software environment for integrated models of biomolecular interaction networks | Q24515682 |
| Proposed minimum reporting standards for chemical analysis | Q27921801 | ||
| The Taverna workflow suite: designing and executing workflows of Web Services on the desktop, web or in the cloud | Q28290043 | ||
| Mining biological pathways using WikiPathways web services | Q28475866 | ||
| Is glutamine still an important precursor of citrulline? | Q42863227 | ||
| WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research | Q42896569 | ||
| A 3 months mild functional test regime does not affect disease parameters in young mdx mice. | Q43121834 | ||
| Metabolic profiling of genetic disorders: a multitissue (1)H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue | Q43617337 | ||
| Muscle genome-wide expression profiling during disease evolution in mdx mice. | Q44471658 | ||
| Eteplirsen for the treatment of Duchenne muscular dystrophy | Q45855674 | ||
| Mutation spectrum leading to an attenuated phenotype in dystrophinopathies | Q45885634 | ||
| A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Q46102101 | ||
| Association of cultured myotubes and fasting plasma metabolite profiles with mitochondrial dysfunction in type 2 diabetes subjects. | Q46333323 | ||
| Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches | Q47105209 | ||
| Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. | Q47115483 | ||
| Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: In vitro, high resolution NMR spectroscopy based analysis. | Q47247792 | ||
| Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy. | Q50019659 | ||
| Expression profiling of disease progression in canine model of Duchenne muscular dystrophy. | Q52648781 | ||
| Metabolic status of patients with muscular dystrophy in early phase of the disease: In vitro, high resolution NMR spectroscopy based metabolomics analysis of serum. | Q53629472 | ||
| Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry | Q56974325 | ||
| Metabolomic Analyses Reveal Extensive Progenitor Cell Deficiencies in a Mouse Model of Duchenne Muscular Dystrophy | Q57039432 | ||
| Fibronectin is a serum biomarker for Duchenne muscular dystrophy | Q57389875 | ||
| Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression | Q57588305 | ||
| Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies | Q57831005 | ||
| Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains | Q58223865 | ||
| Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD | Q58767734 | ||
| MicroRNAs Involved in Molecular Circuitries Relevant for the Duchenne Muscular Dystrophy Pathogenesis Are Controlled by the Dystrophin/nNOS Pathway | Q62722983 | ||
| The "Usual Suspects": Genes for Inflammation, Fibrosis, Regeneration, and Muscle Strength Modify Duchenne Muscular Dystrophy. | Q64957976 | ||
| 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport | Q68215518 | ||
| 31P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes | Q69702971 | ||
| Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine | Q71616065 | ||
| Metabolic profile of dystrophic mdx mouse muscles analyzed with in vitro magnetic resonance spectroscopy (MRS) | Q84311499 | ||
| Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients | Q85261421 | ||
| Muscular dystrophies | Q86291937 | ||
| Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne | Q91923418 | ||
| Age-dependent changes in metabolite profile and lipid saturation in dystrophic mice | Q92219589 | ||
| The RNA binding protein HuR influences skeletal muscle metabolic flexibility in rodents and humans | Q92294036 | ||
| Dystrophinopathy-associated dysfunction of Krebs cycle metabolism | Q93370693 | ||
| Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation | Q28817525 | ||
| Centering, scaling, and transformations: improving the biological information content of metabolomics data | Q31043704 | ||
| Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. | Q33398588 | ||
| Glutamine synthetase in muscle is required for glutamine production during fasting and extrahepatic ammonia detoxification. | Q33744557 | ||
| Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies | Q33991470 | ||
| Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. | Q34089197 | ||
| A web-accessible complete transcriptome of normal human and DMD muscle | Q34147123 | ||
| Glutamine and glutamate as vital metabolites | Q34174552 | ||
| Glutamine: a major energy source for cultured mammalian cells. | Q34266411 | ||
| European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene | Q34453228 | ||
| Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients | Q34555477 | ||
| Multiple testing with minimal assumptions | Q35051488 | ||
| Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy | Q35055089 | ||
| Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy | Q35740280 | ||
| Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study. | Q35901453 | ||
| Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy | Q36221574 | ||
| Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics | Q36305436 | ||
| Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology | Q36360412 | ||
| Structural Basis of Neuronal Nitric-oxide Synthase Interaction with Dystrophin Repeats 16 and 17. | Q36444111 | ||
| Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial | Q37150891 | ||
| Glutamine as indispensable nutrient in oncology: experimental and clinical evidence | Q37638357 | ||
| Identification of serum protein biomarkers for utrophin based DMD therapy | Q37676311 | ||
| Muscular dystrophy: new challenges and review of the current clinical trials. | Q38163300 | ||
| Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy | Q38302852 | ||
| A global test for groups of genes: testing association with a clinical outcome | Q38522319 | ||
| Reduced serum myostatin concentrations associated with genetic muscle disease progression | Q39028061 | ||
| Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients | Q40198410 | ||
| Non-Targeted Metabolomics Analysis of Golden Retriever Muscular Dystrophy-Affected Muscles Reveals Alterations in Arginine and Proline Metabolism, and Elevations in Glutamic and Oleic Acid In Vivo | Q40490992 | ||
| Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy | Q41158405 | ||
| Second-generation compound for the modulation of utrophin in the therapy of DMD. | Q41374222 | ||
| Leptin and metabolic syndrome in patients with Duchenne/Becker muscular dystrophy | Q41622197 | ||
| miRNAs as serum biomarkers for Duchenne muscular dystrophy | Q42126374 | ||
| Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study | Q42413209 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | Cytoscape | Q3699942 |
| P433 | issue | 5 | |
| P921 | main subject | Duchenne muscular dystrophy | Q1648484 |
| P304 | page(s) | 745-755 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models | |
| P478 | volume | 29 |
| Q97423855 | Circulating Biomarkers in Muscular Dystrophies: Disease and Therapy Monitoring | cites work | P2860 |
Search more.